Nasdaq

Evaxion doses first patient in extension of phase 2 trial exploring the full potential of AI-designed personalized cancer vaccine EVX-01

Generation of additional clinical data allows for a more comprehensive assessment of the full potential of EVX-01, while strengthening the already strong clinical data package Will provide insights ...
Nasdaq

Veru Reports Positive Results from Phase 2b QUALITY and Maintenance Extension Study Showing Enobosarm Significantly Reduced Body Weight Regain, Prevented Fat Regain, and ...

MIAMI, FL, June 24, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic ...

Evaxion announces last patient visit in one-year extension of phase 2 trial with personalized cancer vaccine EVX-01

Trial extension completed as planned with three-year clinical efficacy data expected to be presented in the second half of 2026The trial has already yielded encouraging one- and two-year data ...
Seeking Alpha

Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis

– At Week 144, 92.3% of Patients Remained Free of 12-Week Confirmed Disability Worsening (CDW) With 92.7% Remaining Free of 24-Week CDW – – Vidofludimus Calcium Continues to Demonstrate Favorable ...
Seeking Alpha

Corvus outlines January data readout for soquelitinib extension study as Phase II atopic dermatitis trial set for Q1 2026

Management reaffirmed that the soquelitinib Phase II atopic dermatitis trial will begin in early Q1 2026, enrolling approximately 200 patients across 70 global sites and including those who have ...
Sarasota Herald-Tribune

FDA Feedback Supports Extension Phase for Jaguar Health’s Clinical Trial of Crofelemer for Treatment of Microvillus Inclusion Disease (MVID)

SAN FRANCISCO, CA / ACCESS Newswire / March 18, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) family company Napo Pharmaceuticals (Napo) today announced that, based on the U.S. Food and Drug ...